Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.714%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: Angle CEO, finance chief join capital raise

Tue, 19th Jul 2022 16:35

(Sharecast News) - Liquid biopsy specialist Angle had two entries on the list of director buys on Tuesday, after its chief executive and chief financial officers invested in shares.

The AIM-traded firm said CEO Andrew Newland bought 125,000 shares for 80p each, spending a total of £100,000.

At the same time, its CFO Ian Griffiths spent £30,000 on 37,500 shares, also at 80p apiece.

Both transactions took place off-market, as part of the company's capital raise of £20.13m through a placing, retail offer and management subscription, announced on Friday.

Reporting by Josh White at Sharecast.com.

Top Director Buys

Alphawave Ip Group (AWE)

Director name: Sutardja,Sehat

Amount purchased: 538,867 @ 121.84p

Value: £656,555.55

Angle (AGL)

Director name: Newland,Andrew D

Amount purchased: 125,000 @ 80.00p

Value: £100,000.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 10,000 @ 887.70p

Value: £88,770.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 10,000 @ 871.54p

Value: £87,154.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 4,000 @ 877.10p

Value: £35,084.00

Angle (AGL)

Director name: Griffiths,Ian F

Amount purchased: 37,500 @ 80.00p

Value: £30,000.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,816 @ 887.54p

Value: £24,993.13

Schroder British Opportunities Trust (SBO)

Director name: Bartlett,Diana Dyer

Amount purchased: 26,345 @ 75.50p

Value: £19,890.47

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,000 @ 960.00p

Value: £19,200.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,000 @ 956.58p

Value: £19,131.60

More Acquisitions (TMOR)

Director name: McIllree ,Roderick

Amount purchased: 2,000,000 @ 0.95p

Value: £18,900.00

Schroder British Opportunities Trust (SBO)

Director name: England,Neil

Amount purchased: 25,000 @ 75.15p

Value: £18,787.50

Audioboom Group (BOOM)

Director name: Last,Stuart

Amount purchased: 1,218 @ 820.00p

Value: £9,987.60

Audioboom Group (BOOM)

Director name: Last,Stuart

Amount purchased: 1,410 @ 708.25p

Value: £9,986.32

Audioboom Group (BOOM)

Director name: Tobin,Michael

Amount purchased: 1,117 @ 850.00p

Value: £9,494.50

Genflow Biosciences (GENF)

Director name: Leire,Eric

Amount purchased: 308,999 @ 3.03p

Value: £9,362.67

Velocys Plc (VLS)

Director name: Sanderson,Philip

Amount purchased: 200,000 @ 4.30p

Value: £8,600.00

Time Finance (TIME)

Director name: Roberts ,James

Amount purchased: 26,972 @ 18.50p

Value: £4,989.82

Schroder British Opportunities Trust (SBO)

Director name: Jenkinson,Tim

Amount purchased: 6,609 @ 75.15p

Value: £4,966.53

Schroder British Opportunities Trust (SBO)

Director name: OBE,Christopher Keljik,

Amount purchased: 6,577 @ 75.50p

Value: £4,965.50

Time Finance (TIME)

Director name: Telling,Julian

Amount purchased: 26,000 @ 18.85p

Value: £4,901.00

Coca-cola Hbc Ag (cdi) (CCH)

Director name: Bogdanovic,Zoran

Amount purchased: 218 @ 1,956.75p

Value: £4,265.71

Time Finance (TIME)

Director name: Raynes ,Tanya

Amount purchased: 21,156 @ 18.85p

Value: £3,987.91

Bae Systems (BA.)

Director name: Woodburn,Charles

Amount purchased: 19 @ 804.96p

Value: £152.94

Bae Systems (BA.)

Director name: Greve,Brad

Amount purchased: 19 @ 804.96p

Value: £152.94

(HWG)

Director name: Birch,Chris

Amount purchased: 107 @ 140.00p

Value: £149.80

(HWG)

Director name: Patmore,Katerina

Amount purchased: 107 @ 140.00p

Value: £149.80

(HWG)

Director name: Shillaw,Lynda

Amount purchased: 107 @ 140.00p

Value: £149.80

More News
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more
28 Feb 2019 13:30

Angle Enrolls First Patients In Ovarian Cancer Study

LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a

Read more
25 Feb 2019 10:51

Angle client demonstrates new use for 'Parsortix' system

(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.